Paediatric Hepatic International Tumour Trial
-
- Honda Shohei
- Gastroenterological Surgery I, Hokkaido University Hospital Japan Children’s Cancer Group
-
- Hishiki Tomoro
- Japan Children’s Cancer Group
-
- Yokoi Akiko
- Japan Children’s Cancer Group
-
- Kazama Takuro
- Japan Children’s Cancer Group
-
- Takama Yuichi
- Japan Children’s Cancer Group
-
- Hoshino Ken
- Japan Children’s Cancer Group
-
- Taguchi Tomoaki
- Japan Children’s Cancer Group
-
- Hiyama Eiso
- Japan Children’s Cancer Group
Bibliographic Information
- Other Title
-
- 小児肝腫瘍に対するPHIT Trial
- —Decision guidelines for surgical intervention—
- ―外科療法ガイドライン―
Search this article
Abstract
<p>The Paediatric Hepatic International Tumour Trial (PHITT) is a collaborative trial involving three major clinical groups running pediatric liver tumor trials. The aim of the PHITT is to build on the cooperative experience of different consortia to undertake four randomized comparisons of groups of patients with tumors (hepatoblastoma (HB) and hepatocellular carcinoma (HCC)). Decision guidelines for surgical intervention are based on the PRETEXT system and established to evaluate whether reducing treatment doses for low-risk patients maintains their excellent EFS and decreases acute and long-term toxicity. Intensification of therapy with the use of novel agents will be evaluated in a high-risk group. A real-time consultation system will be established to help a local team refer their patients with advanced HB/HCC to a transplant team for further treatment. Selection of the appropriate patients for consideration for up-front surgery requires good imaging during diagnosis and a careful radiological review, anticipating clear resection margins especially in areas adjacent to vascular structures (≧1 cm to the middle hepatic vein). Histological confirmation of HB is required except in emergency situations where the patient is too ill to safely undergo a biopsy. Within the trial, a surgical review study will be included to evaluate the surgical treatment of POST-TEXT III and IV HB. Data obtained from this study will be the basis for assessing the optimal surgical approach for these complex tumors. It is expected that the trial will improve the outcomes in patients with advanced HB/HCC.</p>
Journal
-
- The Japanese Journal of Pediatric Hematology / Oncology
-
The Japanese Journal of Pediatric Hematology / Oncology 56 (2), 107-112, 2019
The Japanese Society of Pediatric Hematology / Oncology
- Tweet
Details 詳細情報について
-
- CRID
- 1390001277348311424
-
- NII Article ID
- 130007705304
-
- ISSN
- 21895384
- 2187011X
-
- Text Lang
- en
-
- Data Source
-
- JaLC
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed